Gross Law Firm seeks Regeneron shareholders for securities class action
The notice says investors who bought Regeneron shares during the stated class period may seek lead-plaintiff status in a case over alleged misleading statements about the Phase III Fianlimab-Libtayo study.
The Gross Law Firm says Regeneron shareholders may contact the firm about a securities class action tied to the company’s Phase III Fianlimab-Libtayo study.
A notice published Aug. 18 by PR Newswire says investors who bought Regeneron Pharmaceuticals shares during the class period may ask about possible lead-plaintiff appointment in the case. The notice lists the class period as Aug. 1, 2025, to May 15, 2026.
It says the proposed class action centers on claims that Regeneron made overly positive statements while concealing adverse facts about the study’s prospects. The notice also says the company’s stock fell after two disclosures cited in the notice, including a change to the analysis population on April 29, 2026, and the company’s May 15, 2026 announcement that the trial did not reach statistical significance for progression-free survival.
According to the notice, the alleged problems included flawed preliminary statistical assumptions, a treatment arm that was not showing meaningful clinical separation from standard therapies, and an expectation that the study would miss its primary endpoint even without any overperformance in the control arm. The notice says those claims are part of the proposed securities class action, but it does not include a court ruling on the merits.
The notice says Regeneron disclosed on April 29, 2026, during its first-quarter earnings call, that the Phase III Fianlimab-Libtayo study had been altered to expand the number of patients eligible for analysis of progression-free survival. It says REGN closed at $731.77 on April 28 and $686.36 on April 29, a one-day decline of about 6.2%.
It also says Regeneron announced on May 15, 2026, that the Phase 3 trial did not reach statistical significance for improvement in progression-free survival. The notice says the shares closed at $698.25 that day and at $629.68 on May 18, a decline of about 9.8% over that period.
The Gross Law Firm notice says there is no cost or obligation to participate and that being named lead plaintiff is not required to share in any recovery. It gives Sept. 14, 2026, as the deadline to seek lead-plaintiff appointment.
The notice is a lawyer advertisement, not a court filing, and it reflects the firm’s allegations. Regeneron was identified in the notice as Regeneron Pharmaceuticals, Inc., with the ticker NASDAQ: REGN.
Investors who believe they were affected would need to act before Sept. 14, 2026, according to the notice.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
Comments ()